Both Wegovy and Pepto-Bismol offer similar effectiveness in symptom control, with the main difference being how quickly they act. Either drug is a viable option depending on the patient’s needs.

Both Wegovy and Pepto-Bismol have similar safety profiles, with mild and transient side effects. Neither presents significant long-term safety concerns.

Both Wegovy and Pepto-Bismol have a low risk of addiction when used correctly under medical supervision, with minimal potential for misuse.

Pepto-Bismol offers greater flexibility with different delivery forms, making it suitable for patients with specific preferences or medical needs.

Both Wegovy and Pepto-Bismol have some contraindications based on individual health conditions, but neither has significantly more restrictions than the other.

Both drugs offer advantages depending on treatment goals. Wegovy is great for fast relief, while Pepto-Bismol is better for long-term management. The choice depends on the patient’s specific needs.